OmniActive to Present New ‘Metabolic Synergizer’ Findings

The randomized, placebo-controlled, double-blind trial was performed on normal, healthy individuals.

"Our purpose was to evaluate the acute effect of Salacia extract (SE), an alpha-glucosidase inhibitor, on glucose and insulin response (to an oral sucrose load) in healthy individuals," stated Dr. Jayant Deshpande, CTO of OmniActive Health Technologies. "Through its ability to inhibit alpha-glucosidase enzyme, SE shows tremendous potential to support healthy blood glucose and insulin levels by decreasing carbohydrate absorption."

 

OmniLean Salacia Extract experienced a successful market launch earlier this month at Engredea/Natural Products Expo 2016 at Anaheim, California.

 

OmniLean is a free-flowing powder for a variety of applications including tablets, capsules and powders – e.g. meal replacements, protein, etc.

 

"OmniLean is a scientifically validated ingredient that represents a new class of ingredients from OmniActive which we call 'metabolic synergizers'," said Lynda Doyle, VP of Global Marketing, OmniActive Health Technologies. "OmniLean is truly a unique ingredient for metabolic health, and there has been strong interest since its introduction to the market."
OmniLean provides a comprehensive approach to achieving multiple objectives of healthy metabolism including healthy carbohydrate metabolism, fat metabolism, heart health and weight management in one convenient, low dose ingredient from a traceable, reliable supply chain.

 

OmniActive state that their unique PlantActive verification process standardizes both bioactives and bioactivity to ensure consistent performance of OmniLean.